# US 10,307,411 B2 · Use of cotinine in treating or preventing neurogenesis deficits and enhancing neurogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,411 B2
- Document ID: US10307411B2
- Status: Granted
- Kind: B2
- Application number: 15/583,937
- Filed: 2017-05-01
- Published: 2017-10-19
- Granted: 2019-06-04
- Earliest claimed: 2014-10-31
- Assignees: The United States of America as represented by the Department of Veterans Affairs; University of South Florida
- Applicants: Department of Veterans Affairs; University of South Florida
- Inventors: Valentina Echeverria Moran; Doreen Appunn
- Web page: https://patentgrep.com/patent/US10307411B2

## CPC

- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of inhibiting or treating chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction.

## Claims

### Claim 1

A method of reducing chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction, wherein the therapeutically effective amount of cotinine is about 0.1 mg/kg to about 10 mg/kg.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cognitive dysfunction includes memory loss and/or depression.

### Claim 3

A method of reducing chemotherapy-induced memory loss or depression comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced memory loss or depression, wherein the therapeutically effective amount of cotinine is about 0.1 mg/kg to about 10 mg/kg.

### Claim 4 (depends on 3)

The method of claim 3, wherein administration of the therapeutically effective amount of cotinine to the cancer patient enhances the recovery of chemotherapy-induced weight loss.

### Claim 5 (depends on 3)

The method of claim 3, wherein administration of the therapeutically effective amount of cotinine to the cancer patient restores weight.

### Claim 6 (depends on 5)

The method of claim 5, wherein weight is restored at a rate faster than in absence of cotinine.

### Claim 7 (depends on 5)

The method of claim 5, wherein weight is restored to a greater extent or higher level than in absence of cotinine.

### Claim 8 (depends on 3)

The method of claim 3, wherein the cotinine is administered intramuscularly, intraperitoneally or orally.

### Claim 9 (depends on 3)

The method of claim 3, wherein the cotinine is administered at the same time, before or after administration of a chemotherapeutic agent.

### Claim 10 (depends on 3)

The method of claim 3, wherein the cotinine is administered by the same route as a chemotherapeutic agent.

### Claim 11 (depends on 3)

The method of claim 3, wherein the therapeutically effective amount of cotinine modulates energy balance in a cancer patient afflicted with chemotherapy-induced weight loss.

### Claim 12 (depends on 3)

The method of claim 3, wherein weight is restored to a weight prior to administration of a chemotherapeutic agent used to treat cancer in a cancer patient subjected to chemotherapy.

### Claim 13

A method of reducing chemotherapy-induced memory loss or depression comprising administering a therapeutically effective amount of cotinine to a cancer patient prior to chemotherapy or prior to onset of chemotherapy-induced memory loss or depression, wherein the therapeutically effective amount of cotinine is about 0.1 mg/kg to about 10 mg/kg.

### Claim 14 (depends on 13)

The method of claim 13, wherein administration of the therapeutically effective amount of cotinine to the cancer patient reduces chemotherapy-induced weight loss or gain in the cancer patient.

### Claim 15 (depends on 14)

The method of claim 14, wherein the chemotherapy-induced weight loss is between 8% to 15% body weight in the cancer patient prior to the administration of the therapeutically effective amount of cotinine.

### Claim 16 (depends on 13)

The method of claim 13, wherein administration of the therapeutically effective amount of cotinine to the cancer patient maintains the cancer patient's weight.

### Claim 17 (depends on 13)

The method of claim 13, wherein weight is maintained to a level higher with cotinine administration than without cotinine administration in a cancer patient treated with a chemotherapeutic agent for the cancer.

### Claim 18 (depends on 16)

The method of claim 16, wherein the cotinine is administered during the course of chemotherapy.